Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 7, 2025Reviews in Cardiovascular MedicineOpen Access

Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum: A Review of Current Clinical Evidence

View Full Paper
Ask AI
Bookmark
Share

Authors

PSPanagiotis StachteasANAthina NasoufidouPKPaschalis Karakasis

Discussion

Loading...

Member takes

Overview

This review demonstrates improvements in glycated hemoglobin and body weight in patients, suggesting dual receptor agonists could transform cardiometabolic disease management.

Key Points

  • Dual glucagon and GLP-1 receptor agonists showed significant improvements in glycated hemoglobin levels and body weight.
  • Emerging evidence indicates these agents may enhance cardiovascular and renal outcomes in high-risk patients.
  • Clinical trials with survodutide and cotadutide outperform traditional therapies in efficacy metrics.
  • These next-generation treatments could redefine standards in precision medicine for metabolic diseases.

Cite This Study

Stachteas et al. (2025) studied this question.

synapsesocial.com/papers/689a0fa0e6551bb0af8d1a41https://doi.org/10.31083/rcm39691
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Emerging concepts in obesity management: focus on glucagon receptor agonist combinations2025
  2. 2Engineered nutrient-stimulated hormonal multi-agonist for precision targeting of obesity and metabolic disorders2025
  3. 3Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management2025 · 8 citations
  4. 4Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation2025
  5. 5GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity2025